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Abstract 
 
Purpose 
Proton pump inhibitors (PPIs), both prescription and over-the-counter, are widely used for the 
treatment of acid-related disease states such as dyspepsia, gastroesophageal reflex disease, 
esophagitis, and peptic ulcers. These medications are generally considered safe in most patient 
populations; however, there are several adverse effects that may occur with long-term use. 
Hypomagnesemia is a newer complication, arising in the literature following multiple case 
reports over the past several years; the true incidence of hypomagnesemia associated with PPI 
use, however, remains unclear at this time. 
Methods 
A retrospective chart review was performed on patients enrolled at the Huntington Veterans 
Affairs Medical Center (VAMC) who are receiving or have received long-term PPI therapy 
(considered > 3 months). Magnesium levels were reviewed to determine the incidence of 
hypomagnesemia with PPI use. Other data analyzed included age, PPI prescribed, calcium level, 
potassium level, and diuretic use (both Loop and thiazide).  
Results  
Three hundred thirty one patients were identified and reviewed that had a prescription for a PPI 
for 3 months or longer, between 2000 and 2014.  Of the 331 patient charts reviewed, 192 met the 
study inclusion criteria and were analyzed for hypomagnesemia while on PPI therapy. There was 
a total of 51 out of 192 patients (26.6%) with hypomagnesemia reported at least 3 months after 
starting PPI therapy. The decline in magnesium levels over time while on PPI therapy resulted in 
a Pearson’s Correlation of    -0.24 which was statistically significant (p<0.001). The average age 
of patients was similar between those with a low magnesium compared to those with a normal 
magnesium, 65.9 years old and 67.4 years old, respectively (p=0.33). Serum potassium and 
calcium levels were almost identical in those with hypomagnesemia compared to those with a 
normal magnesium level (p=0.38 and p=0.57, respectively). Diuretic use was higher in those 
with a low magnesium at 62.7% compared to 53.9% in those with a normal magnesium, although 
this was not statistically significant (p=0.28). When magnesium levels in those without diuretic 
therapy were reviewed, a Pearson’s correlation of -0.18 was found (p=0.10). A stronger 
correlation was found if a patient was on diuretic therapy which resulted in a Pearson’s 
Correlation of -0.32 and this was statistically significant (p=0.001).  Using a logistic regression 
model, it was estimated that each month of combination PPI and diuretic therapy resulted in a 
1.5% higher risk of hypomagnesemia.  
Conclusion 
In conclusion, hypomagnesemia may result in patients on long-term PPI therapy regardless of 
age and diuretics may further contribute to this issue. Low magnesium does not appear to be 
correlated with hypokalemia or hypocalcemia in this patient population. Baseline and routine 
monitoring of magnesium should be considered in patients that are being started on PPI therapy 
or are continued on therapy long-term. Additional studies would be helpful in determining the 
incidence of hypomagnesemia with the addition of a PPI in patients already prone to this 
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problem. The use and effectiveness of magnesium supplementation in those with 
hypomagnesemia while on a PPI should be evaluated to determine if patients should be on long-
term supplementation or if alternative antacid therapy should be considered.  
Keywords 
Hypomagnesemia, proton pump inhibitors 
Introduction and Background Information 
 
Proton pump inhibitors (PPIs), both prescription and over-the-counter, are widely used for the 
treatment of acid-related disease states such as dyspepsia, gastroesophageal reflex disease, 
esophagitis, and peptic ulcers. These medications are generally considered safe in most patient 
populations. Potential mild, self-limiting side effects include abdominal pain, flatulence, 
constipation, and diarrhea; however, there are several adverse effects that may occur with long-
term use. These include nutritional deficiencies such as calcium, iron, and vitamin B12, 
pneumonia or Clostridium difficile infections, and even an increased risk of colon and gastric 
cancers. Hypomagnesemia is a newer complication arising in the literature following multiple 
case reports over the past several years; the true incidence of hypomagnesemia associated with 
PPI use, however, is still unclear at this time. 
 
Magnesium is the second most abundant intracellular cation in the body. Magnesium 
homeostasis is maintained through gastrointestinal absorption and renal excretion. 
Gastrointestinal absorption involves both passive and active movement of magnesium. A serum 
magnesium level is often used to determine a person’s magnesium level within the body and 
determine if supplementation is needed; however, roughly 0.3% of total magnesium is found 
within the serum. The overwhelmingly majority of magnesium is found in bone, muscle, and 
non-muscular soft tissue and accounts for about 99% of total body stores. Serum magnesium can 
be helpful for detecting rapid extracellular changes of magnesium.1  
 
Hypomagnesemia associated with PPI use was first described in 2006 involving two case 
reports.2  After receiving continuous case reports over the past years, the FDA issued a warning 
in 2011 announcing the association between long-term PPI use and hypomagnesemia.3 PPIs are 
thought to affect passive absorption by disrupting the transient receptor potential melastatin-6 
and -7 channels  (TRPM6/7). This disruption is believed to be caused by affecting the transport 
channels directly and/or altering gastrointestinal pH causing a reduction of the ionized vs. 
unionized ratio, ultimately decreasing the affinity and absorption of magnesium by TRPM6/7 
channels .4,5 Hypomagnesemia from use of PPIs is considered a long-term complication that can 
take months or years to develop with no clear dose relationship. Most case reports occurred after 
one year of PPI treatment, but there are some reports of hypomagnesemia occurring in patients as 
early as 3 months after starting therapy.5  
 
Recent studies involving PPIs and magnesium levels have led to slightly conflicting results. 
Danziger et al reviewed 2,632 adult ICU admissions in patients on PPI therapy. They determined 
that low magnesium was limited to those who were also on diuretic therapy.6 Koulouridis et al 
reviewed 402 adult admissions who had hypomagnesemia upon arrival. They concluded out-of-
hospital PPI use was not associated with low magnesium level.7 Luk et al reviewed 66,102 adult 
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admissions and found 693 patients on PPI therapy who also had a low magnesium.  They 
estimated PPI-associated hypomagnesemia to be roughly 1% and that this risk was increased in 
males and the elderly population. They also concluded that it was associated with hypocalcemia 
and hypokalemia.8 Most recently, Zipursky et al compared 366 patients hospitalized with low 
magnesium to 1,464 matched controls. They determined that concomitant PPI and diuretic 
therapy lead to a small increased risk of hospitalization with hypomagnesemia.9 
 
Low magnesium can cause both minor and serious complications depending on the severity. 
Symptoms may range from gastrointestinal upset, weakness, and cramping to metabolic 
abnormalities, cognitive changes, seizures, and arrhythmias. Although most mild cases go 
unnoticed, more severe cases could result in life-threatening events. Magnesium is not a 
component of the electrolyte 7 panel most commonly drawn at the Huntington VAMC. 
Magnesium requires a separate order and is often checked when a patient’s level is expected to 
be out of the normal range. The association between PPIs and low magnesium may warrant more 
frequent monitoring in patients on long-term therapy. 
 
Methods 
 
A retrospective chart review was performed on patients entrolled at the Huntington VAMC who 
are receiving or have received long-term PPI therapy (considered > 3 months). Magnesium levels 
were reviewed to determine the incidence of hypomagnesemia with PPI use. Hypomagnesemia 
was determined to be less than 1.8 mg/dl (normal range 1.8 to 2.4 mg/dl). Other data analyzed 
included age, PPI prescribed, calcium level, potassium level, and diuretic use (both Loop and 
thiazide). Hypokalemia was determined to be less than 3.5 mmol/L (normal range 3.5-5.0 
mmol/L) and hypocalcemia was determined to be less than 8.4 mg/dl (normal range 8.4-10.7 
mg/dl).  
 
The primary endpoint of the study was to determine the incidence of hypomagnesemia with 
long-term PPI therapy. Secondary endpoints included the association of hypoglycemia based on 
patients’ age, association with hypokalemia and/or hypocalcemia, and association with diuretic 
use. Patients were included in the study if they were 18-89 years of age, had a PPI prescription 
for at least 3 months, and had a magnesium level reported at least 3 months after starting PPI 
therapy. Patients were excluded from the study if they were on magnesium supplementation or 
had one of the following: abdominal surgery, acute or chronic diarrhea, alcoholism, chronic 
inflammatory bowel disease, end-stage renal disease requiring dialysis or transplant, pancreatitis, 
or primary hypoparathyroidism as these alone may place a patient at risk of hypomagnesemia.  
 
Results 
 
Three hundred thirty one patients were identified and reviewed that had a prescription for a PPI 
for 3 months or longer. Of the 331 charts reviewed, 139 patients were excluded based on the 
reasons listed in Figure 1.  
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Figure 1. Veterans Affair chart reviewed.  
 
 
 
The remaining 192 patients met the study inclusion criteria and were analyzed for 
hypomagnesemia while on PPI therapy. The most common PPI utilized was omeprazole at 
85.9% (Table 1). A total of 121 concomitant diuretics were used and are shown in Table 2. Fifty 
one percent of patients were on one Loop or thiazide diuretic at the time serum magnesium was 
obtained and only 5.2% of patients were on two diuretics (Table 3).  
 
Table 1. Number of Patients on Different Types of PPI  
 
Table 2.  Number of Patients on Diuretics  and Type.  
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Table 3.  Number of Patients on Diuretic. 
 
 
The average time to collection of  magnesium was 46 months after starting a PPI. Common 
reasons a patient’s serum magnesium was checked include cardiac abnormalities, hypokalemia, 
cramps, generalized weakness, seizure activity, history of alcoholism, or routine clinic visits. 
There were a total of 51 out of 192 patients (26.6%) with hypomagnesemia reported at least 3 
months after starting PPI therapy (Figure 2).  
 
Figure 2. Incidence of Hypomagnesemia 
26.6%
73.4%
Incidence of Hypomagnesemia
Mg less than 1.8 mg/dl
Mg 1.8 mg/dl or greater
 
Figure 3 illustrates the decline in magnesium levels over time while on PPI therapy which 
resulted in a Pearson’s Correlation of -0.24 which was statistically significant (p<0.001). 
Secondary endpoints comparing patients with low magnesium to those with normal magnesium 
can be found in Table 4. The average age of patients was similar between those with a low 
magnesium compared to those with a normal magnesium, 65.9 years old and 67.4 years old, 
respectively (p=0.33). Serum potassium and calcium levels were almost identical between the 
two groups and was also not statistically significant (p=0.38 and p=0.57, respectively). Diuretic 
use was higher in those with a low magnesium at 62.7% compared to 53.9% in those with a 
normal magnesium, although this was not statistically significant (p=0.28).  
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Figure 3. Hypomagnesemia on PPI Therapy Over Time  
 
 
Table 4. Secondary Endpoints Comparing Patients with Low Magnesium to Those with Normal 
Magnesium 
 
Magnesium levels and diuretic use was further analyzed and is illustrated in Figure 4. When 
magnesium levels in those without diuretic therapy were reviewed, a Pearson’s correlation of -
0.18 was found (p=0.10). A stronger correlation was found if a patient was on diuretic therapy 
which resulted in a Pearson’s Correlation of -0.32 and this was statistically significant (p=0.001).  
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Using a logistic regression model, it was estimated that each month of combination PPI and 
diuretic therapy resulted in a 1.5% higher risk of hypomagnesemia.  
 
Figure 4. Comparing Magnesium Levels with Diuretic Use 
 
 
 
Discussion 
 
When reviewing patients on PPI therapy for 3 months or longer, there was a weak correlation 
with hypomagnesemia regardless of age. This effect appears to happen over time regardless of 
diuretic use, but this was stronger when a concomitant diuretic therapy is used.   
Hypomagnesemia did not appear to be correlated with hypokalemia or hypocalemia in these 
specific patients.  
 
An intrinsic factor to keep in mind is that serum magnesium levels were often checked by 
providers when the patient was having potential symptoms related to low levels.  The majority of 
patients were excluded due to no magnesium level after initiation of PPI therapy.  
 
There are several limitations to this study in extrapolating results to the general population since 
the majority of the patients within the VA health system are middle-aged to elderly males. Also, 
those patients already prone to low magnesium levels were excluded in the study so the addition 
of PPI therapy to these types of patients was not analyzed. Patient compliance could not be 
determined due to the retrospective nature of the study. There were three data collections for the 
study which could contribute to some variability; however, this was minimized with a 
standardized data collection sheet. Baseline serum magnesium levels were not utilized and would 
have been useful to determine if certain patients had low magnesium levels prior to PPI use. The 
113
Marshall Journal of Medicine, Vol. 2 [2016], Iss. 3, Art. 13
https://mds.marshall.edu/mjm/vol2/iss3/13
DOI: http://dx.doi.org/10.18590/mjm.2016.vol2.iss3.13
study population was smaller due to limited magnesium levels reported since it is not checked in 
most patients as part of most routine laboratory collections (i.e. electrolyte 7 panel). A larger 
study population may yield more robust results and may detect more significant correlations.   
 
Conclusion   
 
In conclusion, hypomagnesemia may result in patients on long-term PPI therapy regardless of 
age. Diuretics may further contribute to this issue. Low magnesium does not appear to be 
correlated with hypokalemia or hypocalcemia in this patient population. Baseline and routine 
yearly monitoring of magnesium should be considered in patients that are being started on PPI 
therapy or are continued on therapy long-term.  Additional studies would be helpful in 
determining the incidence of hypomagnesemia with the addition of PPI therapy in patients 
already prone to this problem or continued on therapy long-term. The use and effectiveness of 
magnesium supplementation in those with hypomagnesemia while on a PPI should be evaluated 
to determine if patients should be on long-term supplementation. Patients should also be 
carefully evaluated to see long term PPI is really indicated, or if alternative antacid therapy can 
be considered. Patients whom have uncontrolled GERD without long term PPI should be 
evaluated for surgical or endoscopic treatment.   
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